Abstract
Pulmonary embolism (PE) and deep vein thrombosis (DVT) are widely regarded as manifestations of a single disease, venous thromboembolism (VTE). An evidence-based approach to the treatment of acute VTE will be reviewed here. Currently available therapeutic options will be emphasized; possible future treatment approaches will be discussed briefly. The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue.
Keywords: Venous thromboembolism, anticoagulation, thrombolysis, Pulmonary embolism, deep vein thrombosis, vitamin K antagonists, rapid-acting gly-cosaminoglycan agent, fondaparinux, low molecular weight heparin, thrombolytic therapy, activated partial throm-boplastin time, idiopathic VTE, Systemic Thrombolysis, Pulmonary Embolectomy, Dalteparin, Enoxaparin, Tinzaparin, Inferior Vena Cava Interruption, craniotomy, caval thrombosis, DVT, tPA-induced bleeding, thrombotic syndrome, Statins, HmGCoA Reductase inhibitors, C-reactive protein, Aspirin, arterial thrombotic events, myocardial infarction, VKA-based anticoagulation, warfarin
Current Pharmaceutical Design
Title: Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism
Volume: 16 Issue: 31
Author(s): David A. Garcia
Affiliation:
Keywords: Venous thromboembolism, anticoagulation, thrombolysis, Pulmonary embolism, deep vein thrombosis, vitamin K antagonists, rapid-acting gly-cosaminoglycan agent, fondaparinux, low molecular weight heparin, thrombolytic therapy, activated partial throm-boplastin time, idiopathic VTE, Systemic Thrombolysis, Pulmonary Embolectomy, Dalteparin, Enoxaparin, Tinzaparin, Inferior Vena Cava Interruption, craniotomy, caval thrombosis, DVT, tPA-induced bleeding, thrombotic syndrome, Statins, HmGCoA Reductase inhibitors, C-reactive protein, Aspirin, arterial thrombotic events, myocardial infarction, VKA-based anticoagulation, warfarin
Abstract: Pulmonary embolism (PE) and deep vein thrombosis (DVT) are widely regarded as manifestations of a single disease, venous thromboembolism (VTE). An evidence-based approach to the treatment of acute VTE will be reviewed here. Currently available therapeutic options will be emphasized; possible future treatment approaches will be discussed briefly. The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue.
Export Options
About this article
Cite this article as:
A. Garcia David, Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563347
DOI https://dx.doi.org/10.2174/138161210793563347 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Secondary Prevention of Ischemic Stroke
Current Drug Targets Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology The Vasculature as a Target in the Treatment of Pulmonary Emphysema
Current Drug Targets New Technologies: Non-Hormonal Female Contraception
Current Women`s Health Reviews Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews New Anticoagulants: Focus on Venous Thromboembolism
Current Vascular Pharmacology Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Molecular Link between Intravascular Hemolysis and Vascular Occlusion in Sickle Cell Disease
Current Vascular Pharmacology Meet the Editorial Board
Letters in Drug Design & Discovery Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Current Pharmaceutical Biotechnology Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology Myocardial Infarction with and without ST-segment Elevation: a Contemporary Reappraisal of Similarities and Differences
Current Cardiology Reviews Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy
Current Drug Targets Perioperative Safety of Warfarin Therapy and Reversal
Current Drug Safety Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism